Genetic Study in Ovarian Cancer During PARP Inhibitor Therapy
Part of Blood & lymphatic, Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study looks at the genetic changes in ovarian cancer cells before and during treatment with PARP inhibitors. It aims to understand how these changes may affect treatment response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman with advanced ovarian cancer that has shrunk or disappeared after surgery.
- You are eligible to take a PARP inhibitor (a targeted therapy pill) as your first treatment or as maintenance after chemotherapy.
- Your blood cell counts (red cells, white cells, platelets) must be normal before starting the PARP inhibitor.
- Ovarian cancer cells must not have spread to your bone marrow.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for specific gene mutations in the blood of ovarian cancer patients who have a BRCA mutation and are starting first-line maintenance therapy with a PARP inhibitor called Olaparib. It aims to better understand how these mutations may affect treatment response.
This study looks at specific DNA “damage repair” proteins as a marker to understand why some BRCA-mutated breast cancers may resist PARP inhibitor treatment. Your biopsy (or existing biopsy) helps researchers study whether these lab markers relate to how well PARP inhibitors work.
This study looks at how PARP inhibitor maintenance therapy affects survival in people with ovarian, fallopian tube, or peritoneal cancer. It compares outcomes for those newly diagnosed at an advanced stage and those with a first recurrence that responded to platinum chemotherapy.
This study tests a new form of a drug similar to olaparib (Lynparza) in people with BRCA-mutated ovarian cancer. It looks at how the drug works in the body and checks for safety, to see if the new formulation is as effective and safe as the current one.
This study looks at certain “DNA repair traits” (called homologous recombination phenotype) in people with epithelial ovarian cancer. Results may help researchers better understand who responds to platinum chemotherapy, which is commonly used for this cancer.
This trial tests whether olaparib (a pill cancer medicine) works better than standard platinum chemotherapy after a second surgery for recurrent ovarian cancer. It’s for people whose cancer returned after initial PARP-inhibitor (PARPi) maintenance and aims to see if treatment can control the cancer for longer with acceptable side effects.
Hear when a new Leukemia, Myeloid, Acute trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.